產(chǎn)品訂購(gòu)信息：
英文名稱(chēng)  Anti-SERPINA12/Vaspin 

中文名稱(chēng)   內(nèi)臟脂肪組織源性絲氨酸蛋白酶抑制蛋白抗體費(fèi)用 

別    名  OL 64; OL-64; OL64; Serine (or cysteine) proteinase inhibitor clade A (alpha 1 antiproteinase antitrypsin) member 12 ; Serpin A12; Serpin A12 precursor; Serpin peptidase inhibitor clade A (alpha 1 antiproteinase antitrypsin) member 12; Serpina12; SPA12_HUMAN antibody Vaspin; Visceral adipose specific serpin; Visceral adipose tissue derived serine protease inhibitor; Visceral adipose tissue-derived serine protease inhibitor; Visceral adipose-specific serpin.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來(lái)源   Rabbit

克隆類(lèi)型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit 

產(chǎn)品類(lèi)型   一抗  

研究領(lǐng)域    心 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo)

蛋白分子量  predicted molecular weight: 45kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human SERPINA12/Vaspin 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

內(nèi)臟脂肪組織源性絲氨酸蛋白酶抑制蛋白抗體費(fèi)用 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 May modulates insulin action conceivably only in the presence of its yet undefined target proteases in white adipose tissues.

Serpins are the largest and most diverse family of protease inhibitors. Most serpins control proteolytic cascades, certain serpins do not inhibit enzymes, but instead perform diverse functions such as storage (ovalbumin, in egg white), hormone carriage proteins (thyroxine-binding globulin, cortisol-binding globulin) and tumor suppressor genes (maspin). Most inhibitory serpins target chymotrypsin-like serine proteases. These enzymes are defined by the presence of a nucleophilic serine residue in their catalytic site. Some serpins inhibit other classes of protease. A number of such serpins have been shown to target cysteine proteases. These enzymes differ from serine proteases in that they are defined by the presence of a nucleophilic cysteine residue, rather than a serine residue, in their catalytic site.

SerpinA12, also known as OL-64, Visceral adipose tissue-derived serine protease inhibitor, Vaspin, Visceral adipose-specific serpin and SERPINA12, is a secreted protein which belongs to the serpin family. SerpinA12 / Vaspin is expressed in visceral adipose tissues. It may modulates insulin action conceivably only in the presence of its yet undefined target proteases in white adipose tissues. SerpinA12 / Vaspin may be the compensatory molecule in the pathogenesis of metabolic syndrome and SerpinA12 / Vaspin recombinant protein or vaspin-mimicking agents such as vaspin analogs, antibodies or small molecule agents may be the link to drug discovery and development.

Function : May modulates insulin action conceivably only in the presence of its yet undefined target proteases in white adipose tissues.

Subcellular Location : Secreted.

Tissue Specificity : Expressed in visceral adipose tissues.

Similarity : Belongs to the serpin family.

Database links :

UniProtKB/Swiss-Prot: Q8IW75.1

Entrez Gene: 145264 Human

SwissProt: Q8IW75 Human

Unigene: 99476 Human

應(yīng)激誘導(dǎo)磷蛋白1 多克隆抗體  STIP1 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

絲氨酸/蘇氨酸蛋白激酶25 多克隆抗體  STK25 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

絲氨酸/蘇氨酸蛋白激酶3 多克隆抗體  STK3 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

絲氨酸/蘇氨酸蛋白激酶31 多克隆抗體  STK31 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

絲氨酸/蘇氨酸蛋白激酶38 多克隆抗體  STK38 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

α2C-AR腎上腺素能受體抗體     抑制基因LUCA15抗體

中心體蛋白AZI1抗體     抑制基因LPP2抗體

ADCK5蛋白抗體     抑制基因LATS1抗體

細(xì)胞分裂周期蛋白5抗體     抑制蛋白抗體

β淀粉樣肽/Aβ42抗體     抑制蛋白18抗體

整合素β3 多克隆抗體  Integrin β3 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

整合素β3 多克隆抗體  Integrin β3 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

整合素β4 多克隆抗體  Integrin β4 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

整合素β5 多克隆抗體  Integrin β5 Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

Involucrin 多克隆抗體  Involucrin Polyclonal Antibody  700/30ul#1540/100ul#2520/200ul

小蕓木Micromelum sp. Prudomestin 3,5,7-三羥基-8,4'-二甲氧基黃酮 3443-28-5 C17H14O7 ≥97%

遼東楤木皂苷VLicodongcrclicscponinVHPLC≥98%，20mg/支

巴利森苷A Coniferin 62499-28-9 20mg HPLC≥98% 巴利森苷A_62499-28-9用于含量...

含量測(cè)定泮托拉唑100575-200903常溫，避光100mg

Low-Density Polyetxylene 低密度聚標(biāo)準(zhǔn)品9002-

內(nèi)臟脂肪組織源性絲氨酸蛋白酶抑制蛋白抗體費(fèi)用25038-59-9 聚對(duì)本二價(jià)酸乙二酯標(biāo)準(zhǔn)品 3 sips

云南松Pinus yunnanensis (7S,8R)-3′，4,9,9′-四輕基-3-甲氧基-7，8-二輕本并-1′-丙醇基新木脂素 75775-36-9 C19H22O6 ≥95% 甲本噻嗪 雜質(zhì)E(Y0000159

異丙草安標(biāo)準(zhǔn)品 嗪草同脫氧腺苷標(biāo) DADK嗪草同標(biāo)準(zhǔn)品

Clenberol Related Compound B克倫特羅相關(guān)物質(zhì)B標(biāo)準(zhǔn)品37148-49-510mg克倫特羅相關(guān)物質(zhì)B標(biāo)準(zhǔn)品

黃柏堿 6873-13-8 HPLC≥98%;20mg 訂購(gòu)|咨詢(xún)

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 內(nèi)臟脂肪組織源性絲氨酸蛋白酶抑制蛋白抗體費(fèi)用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴(lài)氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）內(nèi)臟脂肪組織源性絲氨酸蛋白酶抑制蛋白抗體費(fèi)用 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線(xiàn),計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。